Bacteremia and meningitis caused by OXA-23-producing Acinetobacter baumannii - molecular characterization and susceptibility testing for alternative antibiotics
- PMID: 29720352
- PMCID: PMC6328846
- DOI: 10.1016/j.bjm.2018.04.002
Bacteremia and meningitis caused by OXA-23-producing Acinetobacter baumannii - molecular characterization and susceptibility testing for alternative antibiotics
Abstract
Background: Carbapenem-resistant Acinetobacter baumannii infection is a concern in developing countries due to high incidence, few therapeutic options, and increasing costs.
Objective: Characterize and analyze the antibiotic susceptibility patterns of carbapenem-resistant A. baumannii isolates and evaluate clinical data of meningitis and bacteremia caused by this microorganism.
Methods: Twenty-six A. baumannii isolates from 23 patients were identified by MALDI-TOF and automated methods and genotyped using pulsed field genotyping electrophoresis. Clinical data and outcomes were evaluated. Susceptibility of isolates to colistin, tigecycline, meropenem, imipenem, and doxycycline was determined.
Results: Mortality due to A. baumannii infections was 73.91%; all patients with meningitis and 7/8 patients with ventilator-associated pneumonia died. All isolates were susceptibility to polymyxin (100%; MIC50, MIC90: 1μg/mL, 1μg/mL) and colistin (100%; MIC50, MIC90: 2μg/mL, 2μg/mL), and 92% were susceptible to tigecycline (MIC50, MIC90: 1μg/mL, 1μg/mL) and doxycycline (MIC50, MIC90: 2μg/mL, 2μg/mL). blaOXA-23 was identified in 24 isolates. Molecular typing showed 8 different patterns: 13 isolates belonged to pattern A (50%).
Conclusion: Carbapenem-resistant A. baumannii infections mortality is high. Alternative antimicrobial therapy (doxycycline) for selected patients with carbapenem-resistant A. baumannii infection should be considered.
Keywords: Acinetobacter baumannii; Carbapenem; Doxycycline; Multidrug resistance; Oxacillinases.
Copyright © 2018 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. All rights reserved.
Figures
Similar articles
-
High prevalence of oxacillinases in clinical multidrug-resistant Acinetobacter baumannii isolates from the Tshwane region, South Africa - an update.BMC Infect Dis. 2015 Nov 14;15:521. doi: 10.1186/s12879-015-1246-8. BMC Infect Dis. 2015. PMID: 26573617 Free PMC article.
-
[Molecular characterization of beta-lactamase-associated resistance in Acinetobacter baumannii strains isolated from clinical samples].Mikrobiyol Bul. 2014 Jul;48(3):365-76. Mikrobiyol Bul. 2014. PMID: 25052103 Turkish.
-
OXA-type Carbapenemases and Susceptibility of Colistin and Tigecycline Among Carbapenem-Resistant Acinetobacter Baumannii Isolates from Patients with Bacteremia in Turkey.Clin Lab. 2015;61(7):741-7. doi: 10.7754/clin.lab.2014.141116. Clin Lab. 2015. PMID: 26299073
-
How should we treat acinetobacter pneumonia?Curr Opin Crit Care. 2019 Oct;25(5):465-472. doi: 10.1097/MCC.0000000000000649. Curr Opin Crit Care. 2019. PMID: 31335380 Review.
-
Acinetobacter baumannii meningitis in children: a case series and literature review.Infection. 2019 Aug;47(4):643-649. doi: 10.1007/s15010-018-1234-1. Epub 2018 Oct 16. Infection. 2019. PMID: 30328074 Review.
Cited by
-
Enteral versus intravenous antibiotics for critically ill patients: A pilot study.Braz J Infect Dis. 2025 Jul-Aug;29(4):104538. doi: 10.1016/j.bjid.2025.104538. Epub 2025 May 14. Braz J Infect Dis. 2025. PMID: 40373667 Free PMC article. Clinical Trial.
-
Individualized optimization of colistin loading doses.J Pharmacokinet Pharmacodyn. 2023 Feb;50(1):11-20. doi: 10.1007/s10928-022-09831-x. Epub 2022 Nov 2. J Pharmacokinet Pharmacodyn. 2023. PMID: 36323974
-
Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PLoS One. 2024 Dec 16;19(12):e0311124. doi: 10.1371/journal.pone.0311124. eCollection 2024. PLoS One. 2024. PMID: 39680587 Free PMC article.
-
Rapid simultaneous detection of bla oxa-23, Ade-B, int-1, and ISCR-1 in multidrug-resistant Acinetobacter baumannii using single-tube multiplex PCR and high resolution melting assay.Infect Drug Resist. 2019 Jun 7;12:1573-1581. doi: 10.2147/IDR.S207225. eCollection 2019. Infect Drug Resist. 2019. PMID: 31289445 Free PMC article.
-
A broad-spectrum beta-lactam-sparing stewardship program in a middle-income country public hospital: antibiotic use and expenditure outcomes and antimicrobial susceptibility profiles.Braz J Infect Dis. 2020 May-Jun;24(3):221-230. doi: 10.1016/j.bjid.2020.05.005. Epub 2020 Jun 3. Braz J Infect Dis. 2020. PMID: 32504551 Free PMC article.
References
-
- Climaco E.C., Oliveira M.L., Pitondo-Silva A. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infect Genet Evol. 2013;19:127–133. - PubMed
-
- Fournier P.E., Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42(5):692–699. - PubMed
-
- Maragakis L.L., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–1263. - PubMed
-
- Fernandez-Cuenca F., Tomas-Carmona M., Caballero-Moyano F. [In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010] Enferm Infec Microbiol Clin. 2013;31(1):4–9. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical